Wintershall Dea and Cognite Enable Domain Experts to Harness Value From Data in the North Sea
In a continued commitment to drive value through digital, Wintershall Dea has agreed with Cognite to deploy Cognite Data Fusion (CDF) to Brage, scaling the Wintershall Dea Data Hub from Germany to Norway.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005336/en/
This effort builds on an existing partnership between the companies. It will allow the ingestion and contextualization of data from the Brage field to build applications which support Wintershall Dea domain experts in decision-making for smart maintenance and production optimization.
An advisory tool to enable dynamic separator capacity limits will be developed to support decisions related to production optimization, thereby increasing throughput & reduced OPEX.
Safety optimization for critical valves will be achieved by moving from calendar-based maintenance to proactive maintenance, by using contextualized data from valves and other safety-critical equipment.
“We look forward to the development of these solutions with Cognite as they are proven technologies, allowing us to add value quickly,” said Christian Eide from Wintershall Dea Norge.
Cognite will collaborate with operational technology (OT) architects, the data integration team and subject matter experts from Wintershall Dea to develop these solutions, leveraging data from CDF.
This collaboration is also laying foundations for further scaling and acceleration of digital initiatives and Wintershall Dea’s Data Hub. The Data Hub ensures a data reference architecture, the critical enabler to scale initiatives across assets, and is leveraging Cognite Data Fusion as an important component.
“This is a perfect example of Cognite Data Fusion being used to empower and assist workers at Wintershall Dea with actual development and solution delivery that leads to a complete handover of the process as they continue to lead the way with their digital agenda,” said John Markus Lervik, president of Cognite.
About Wintershall Dea
Wintershall Dea is Europe’s leading independent natural gas and oil company with more than 120 years of experience as an operator and project partner along the entire E&P value chain. The company with German roots and headquarters in Kassel and Hamburg explores for and produces gas and oil in 13 countries worldwide in an efficient and responsible manner. With activities in Europe, Russia, Latin America and the MENA region (Middle East & North Africa), Wintershall Dea has a global upstream portfolio and, with its participation in natural gas transport, is also active in the midstream business.
Wintershall Dea was formed from the merger of Wintershall Holding GmbH and DEA Deutsche Erdoel AG, in 2019. Today, the company employs around 2,500 people worldwide from over 60 nations.
Cognite is a global industrial software-as-a-service (SaaS) company supporting the full-scale digital transformation of heavy-asset industries around the world. Their key product, Cognite Data Fusion (CDF), empowers companies with contextualized OT/IT data to drive industrial applications that increase safety, sustainability, and efficiency, and drive revenue. Visit us at www.cognite.com and follow us on Twitter @CogniteData or at LinkedIn: https://www.linkedin.com/company/cognitedata
Global Head of Public Relations, Cognite
+1 512 744 3420 (US)
+47 482 90 454
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CureApp SC, Digital Therapeutic for Nicotine Addiction: Introducing a New Form of App-based Prescription Treatment - The Firs t Digital Therapeutic to Be Covered by Japan’s Public Healthcare Insurance System1.12.2020 07:36:00 CET | Press release
CureApp, Inc. (Headquarters: Chuo-ku, Tokyo; CEO: Kohta Satake) has announced that CureApp SC Nicotine Addiction Treatment App and CO Checker (hereafter, CureApp SC) – a treatment app (digital therapeutic) targeting nicotine addiction – is now covered by Japan’s public healthcare insurance system as of December 1, 2020, following a period of clinical trials and regulatory approval. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201130006039/en/ CureApp SC, Digital Therapeutic for Nicotine Addiction Introducing a New Form of App-based Prescription Treatment The First Digital Therapeutic to be Covered by Japan’s Public Healthcare Insurance System (Photo: Business Wire) This marks the first case of a digital therapeutics application being covered by the insurance, as well as the first time that a digital therapeutic in the field of smoking cessation treatments has been covered by a country’s national health insurance system in
Ipsen Highlights New Strategic Priorities and Provides Mid-Term Financial Outlook1.12.2020 07:00:00 CET | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a specialty-care focused biopharmaceutical group, today will host a virtual Capital Markets Day to highlight the Group’s new strategic priorities with the aim of driving continued growth and bringing transformative medicines to patients. David Loew, Chief Executive Officer of Ipsen stated: “Our new Group strategy positions Ipsen for long-term success by focusing together for patients and society. We will reinforce our commitment to Oncology, Rare Disease and Neuroscience by strengthening and accelerating our external innovation efforts and pipeline in clearly-defined segments. Through prioritization and collaboration, we will drive efficiencies to support investment in our pipeline. We are building on a strong foundation of engaged employees, agile development capabilities and global commercial footprint. I am energized to execute on our key strategic priorities to create long-term value for all stakeholders.” Bring the full potential
Process Sensing Technologies, a Battery Ventures Company, Announces New Majority Investment from AEA Investors1.12.2020 06:01:00 CET | Press release
Process Sensing Technologies (“PST”), a global manufacturer of instruments, analyzers and sensors for precision measurement and monitoring in a variety of critical industries, announced that global private-equity firm AEA Investors LP (“AEA”) has made a majority investment in the company. PST backer Battery Ventures will maintain a minority stake in the business. Baird acted as exclusive sell-side advisor; other terms of the transaction were not disclosed. PST—a platform constructed under Battery’s ownership comprising seven global businesses—sells its sensors and other technologies into industries including pharmaceuticals, life sciences, specialty gases, petrochemicals, food-and-beverage, semiconductors and building automation. The company’s products measure moisture, oxygen and pressure, among other things, and help improve customers’ profitability while helping them stay compliant with often-stringent industry regulations. Battery began the PST platform journey with its acquisition
Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited1.12.2020 00:00:00 CET | Press release
Celltrion (KRX:068270) has completed the acquisition of select primary care assets from Takeda Pharmaceutical Company Limited (“Takeda”) in Asia Pacific, igniting efforts to strengthen its R&D capability in the global small molecule pharmaceuticals business. In June, the firms announced an agreement under which Celltrion would acquire 18 "Primary Care" product assets in the Asia Pacific area for a total of USD 278 million inclusive of milestone payments from Takeda. Celltrion proceeded with the acquisition process through its newly established subsidiary in Singapore, "Celltrion Asia Pacific Pte, Ltd."1 ("Celltrion APAC"). Upon completion of the acquisition, Celltrion APAC will assume the ownership of the rights to patents, trademarks, and sales of 18 products sold in 9 markets including South Korea, Thailand, Taiwan, Hong Kong, Macau, the Philippines, Singapore, Malaysia, and Australia. The 18 products include prescription medicines such as Nesina (diabetes), Actos (diabetes), and Eda
Takeda Completes Sale of Select OTC and Non-Core Assets to Celltrion in Asia Pacific1.12.2020 00:00:00 CET | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to Celltrion Inc. (“Celltrion”) for a total value of $278 million USD inclusive of milestone payments. The portfolio includes 18 pharmaceutical products and over-the-counter (OTC) products sold in Asia Pacific, which is part of Takeda’s Growth & Emerging Markets Business Unit. This divestment agreement was first announced in June 2020. The divested portfolio includes pharmaceutical products and OTC products in the Cardiovascular, Diabetes and General Medicine therapeutic areas, sold in Australia, Hong Kong, Macau, Malaysia, Philippines, Singapore, South Korea, Taiwan and Thailand. The products, while addressing key patient needs in these countries and territories, are outside of the business areas Takeda has chosen as core to its global long-term growth. As part of the deal, Takeda will continue to manufacture the portfol
Ipsen Receives FDA Fast Track Designation for Investigational Irinotecan Liposome Injection (ONIVYDE ® ) as a Second-Line Monotherapy Treatment for Small Cell Lung Cancer (SCLC)30.11.2020 22:58:00 CET | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the United States Food and Drug Administration (FDA) has granted the company Fast Track designation for irinotecan liposome injection (ONIVYDE®) in study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen, reflecting the unmet medical need. ONIVYDE® is currently approved in the United States and in Europe in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. ONIVYDE® is not indicated as a single agent for the treatment of patients with metastatic adenocarcinoma of the pancreas. An ongoing Phase III randomized study (RESILIENT; NCT03088813) trial is being conducted to assess the efficacy and safety of investigational irinotecan liposome injection (ONIVYDE®) as a monotherapy for SCLC study patients who have progressed on or a